We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Pooled Saliva Testing for COVID-19 Can Be Cheaper and as Accurate as Individual Nasopharyngeal Diagnostic Tests

By LabMedica International staff writers
Posted on 14 Oct 2021

Testing pooled saliva samples twice weekly for SARS-CoV-2 on a residential college campus yielded a greater than 95% agreement with the gold standard for accuracy—nasopharyngeal diagnostic samples tested singly. More...

The study by researchers at Olivet Nazarene University (Bourbonnais, IL, USA) revealed that at an average of 665 tests per week, the cost, just USD 0.43 per sample, likely remains the least expensive method to date. Using pools of 10 samples, the test provides results in less than eight hours, and is among the most sensitive available, detecting virus at very low viral load, according to the study. This approach enabled successful screening of 43,884 samples, detecting 83% of the semester’s COVID-19 cases. Additionally, the researchers noted that saliva sampling is noninvasive, does not require a transport medium and is stable at room temperature for at least 24 hours.

In the study, students submitted saliva samples once or twice weekly during spring semester, 2021. Saliva samples were collected every weekday before 9am and delivered to the testing lab. Self-collection by students was handled via the honor system, and fewer than 1% of samples were invalid, with 92% submitted on the assigned date. In the study, 36.2% of those tested were asymptomatic, and 48.3 % of participants reported experiencing “very mild” symptoms at the time of testing. This suggests that without the mandatory testing, 84.5% of students might not have gotten tested on their own at the time of screening. Furthermore, only 56% developed flu-like or severe symptoms during their illness. These results raise the possibility that COVID-19 contagion would have swept the college without the testing program.

“Our study demonstrates a significant step forward for achieving rapid test results on a large scale, while preserving supplies and reducing costs,” said study author Daniel R. Sharda, Ph.D. “Our pooled saliva approach puts routine COVID-19 testing within reach for smaller organizations and countries where resources are limited. Future pandemics should use pooled strategies from the very beginning, when tests are otherwise limited.”

Related Links:
Olivet Nazarene University 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Latest trends show that cancer diagnosis is evolving beyond a process focused mainly on medical imaging and microscopic tissue examination toward a more layered approach that incorporates molecular and genomic testing, liquid biopsy, digital pathology, and AI (Image Credit: iStock)

Expanding Screening and Biomarker Testing Drive Cancer Diagnostics Market Growth

Cancer diagnostics encompasses imaging, tissue pathology, laboratory testing, and molecular technologies used to detect, confirm, characterize, and monitor cancer. The global cancer diagnostics market... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.